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Objective:We sought to determine the effect of neoadjuvant chemoradiotherapy followed by surgical interven-
tion on health-related quality of life in patients with esophageal cancer.
Methods: Health-related quality of life was evaluated in a prospective phase II study of neoadjuvant chemora-
diotherapy followed by esophagectomy in 52 patients with carcinoma of the esophagus. Esophagectomy was per-
formed 6 weeks after completion of induction. Functional Assessment of Cancer Therapy–Esophageal scoring
was performed before treatment, 7 weeks after initiation of neoadjuvant therapy, before resection, and at 1, 3,
and 6 months and 1 year after resection.
Results: Forty-three patients completed the entire treatment protocol. Functional Assessment of Cancer Therapy–
Esophageal scores decreased significantly after chemoradiation at week 7 (120 vs 127 at baseline, P ¼ .04) but
returned to baseline levels before surgical intervention (127). Similarly, scores decreased significantly after sur-
gical intervention (115 at 1 month, P¼ .02) but returned to baseline levels by 3 months postoperatively (127). At
1 year postoperatively, there was a statistically significant improvement in scores compared with those at baseline
(139, P ¼ .003). Functional Assessment of Cancer Therapy–Esophageal scores continued to increase over time
for patients who were alive at least 1 year after the operation with or without disease but were observed to sig-
nificantly decrease in those who died within 1 year after the operation (P ¼ .0001). An increase in quality of
life was associated with a significantly lower risk of death (P ¼ .04).
Conclusion: Neoadjuvant therapy has a significant effect on health-related quality of life, but this is transient,
with recovery to baseline within 5 to 7 weeks after completion of induction therapy. Health-related quality of
life decreases again after surgical intervention but returns to baseline levels within 3 months.Earn CME credits at
http://cme.ctsnetjournals.org
The primary objective of this study was to assess the effect
of neoadjuvant chemoradiation followed by surgical inter-
vention for esophageal cancer on health-related quality of
life (HRQOL) by using the Functional Assessment of Can-
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tool to measure the effect of treatment on functional, social,
physical, and emotional well-being that incorporates the
esophageal cancer subscale and allows for a systematic
evaluation of quality of life (QOL) specifically in the con-
text of esophageal cancer.1 A prospective cohort of 52 pa-
tients with esophageal cancer who underwent neoadjuvant
chemoradiation therapy followed by surgical resection
was studied.
With an increasing incidence and an overall survival of
5% to 8%, esophageal cancer is one of the most lethal
malignancies. Although surgical intervention remains the
mainstay of treatment for resectable disease, with a 5-year
survival rate of 25% to 40%,2-8 meta-analyses of neoadju-
vant therapy followed by surgical intervention have sug-
gested a survival benefit, albeit a modest one at best.9
Also, neoadjuvant therapy might improve resectability in
locally advanced disease because of a downstaging effect.10
However, the morbidity associated with neoadjuvant che-
moradiation is significant and entails a prolonged period of
treatment (3 months), which represents almost 20% of the
historical median survival time of 16.3 months.11
This paragraph should be rewritten: The effect of neoad-
juvant treatment on QOL assumes greater significance in
a disease with a poor prognosis, significant treatment related
morbidity and only modest survival benefit. Measurement ofery c January 2009
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EORTC ¼ European Organization for
Research and Treatment and Cancer
FACT-E ¼ Functional Assessment of Cancer
Therapy–Esophageal
HRQOL ¼ health-related quality of life
QOL ¼ quality of life
SF-36 ¼ Short Form–36
outcome solely in terms of survival and cure are insufficient
and the effect of treatment on QOL should be taken into
consideration when making treatment decisions.
MATERIALS AND METHODS
In a prospective phase II trial of neoadjuvant chemoradiotherapy fol-
lowed by surgical intervention at the Toronto General and Princess Mar-
garet Hospitals of the University Health Network, 52 patients were
assessed by using the FACT-E (version 4) before the initiation of treatment
(baseline), 7 to 8 weeks after the start of treatment (7 weeks), before surgical
intervention (12–14 weeks), and 1, 3, 6, and 12 months after surgical inter-
vention. Dysphagia was graded according to the Common Toxicity Criteria,
version 2. The study was approved by the institutional research ethics board,
and informed consent was obtained from all patients. Entry criteria in-
cluded: histological proven squamous carcinoma or adenocarcinoma of
the esophagua or gastroesophageal junction (Siewert type I or II), Eastern
Cooperative Oncology Group performance stage 0-2, clinical TINIM0, or
T2-4N0-1M0 according to the American Joint Commission on Cancer
(AJCC) 2002 staging manual. Patients with Mla disease were included if
the primary tumor was in the distal esophagus or gastroesophageal junction
on the basis that these nodes represented regional nodes. Patients were 18
years of age or older, spoke and understood English, were mentally compe-
tent and were medically fit for the proposed treatment as assessed by the
multidisciplinary team. Treatment consisted of induction chemotherapy
(cisplatin 30mg/m2, irinotecan 65mg/m2 weekly weeks 1 and 2, followed
by concurrent chemotherapy (weeks 4-5, and 7-8) with conformal radiation
(40 Gy) followed by a boost of radiation to a total dose of 50 Gy. If, on re-
staging with computed tomographic scans of the chest and abdomen, there
was no evidence of metastatic or unresectable disease, esophagectomy with
lymphadenectomy was performed 6 weeks after completion of induction.
Tumors of the midesophagus were resected with a McKeown approach. Tu-
mors of the gastroesophageal junction or lower third of the esophagus were
resected with an Ivor–Lewis approach or a left thoracoabdominal approach
with a left neck incision for the anastomosis. En bloc resection was per-
formed, including the overlying mediastinal pleura and periesophageal tis-
sues with 5-cm proximal and distal margins. Lymphadenectomy was
performed, including the mid and lower mediastinal nodes and a D2 dis-
section in the abdomen. Transhiatal esophagectomy was allowed but not
recommended.
This study and the use of all data collected were approved by the research
and ethics board at our institution. Demographic factors and clinical and
pathologic stage were summarized by using median and range (for contin-
uous variables) and frequencies (for categorical variables). The paired t test
was applied to compare the FACT-E scores at different time points. Mixed-
model regression was applied to model the repeated measurement of FACT-
E scores over time and estimate the random intercept and slope of the
FACT-E score. The estimated random slopes were used in the Cox propor-
tional hazard model as predictors for the patients’ overall survival. The sta-
tistical analysis was performed with version 9.1 of the SAS System and
User’s Guide (SAS Institute, Inc, Cary, NC).The Journal of Thoracic andRESULTS
From November 2002 to October 2005, 215 patients with
esophageal cancer presented to our institution, of which 102
were considered operative candidates. Of the operative can-
didates, 68 patients were evaluated for inclusion in the trial,
and 53 were eligible. Only 1 patient declined. The mean age
was 60 years (range, 33–79), and 77%were men. The tumor
was located at the gastroesophageal junction in 15 (29%)
patients and in the thoracic esophagus in 37 (71%) patients.
Histology was adenocarcinoma in 37 (71%) patients, squa-
mous cell carcinoma in 13 (25%) patients, and poorly differ-
entiated large cell carcinoma in 2 (4%) patients. Based on
clinical staging, 12 patients had T2 disease, 35 has T3 dis-
ease, and 5 had T4 disease; 15 patients had N0 disease and
37 had N1 disease; and 41 patients had M0 disease and 11
had M1A disease. The clinical stage at enrollment was IIA
in 13 (25%) patients, IIB in 8 (15%) patients, III in 20
(39%) patients, and IVA in 11 (21%) patients.
Of the 52 enrolled patients, 3 discontinued induction ther-
apy because of toxicity and proceeded directly to surgical
intervention, and 2 refused further treatment during preoper-
ative chemoradiotherapy. There were 2 preoperative deaths
caused by stroke and central line sepsis. Preoperative treat-
ment was completed in 45 patients, but 2 progressed on
and were not treated surgically; the remaining 43 proceeded
to surgical intervention. The median time between the com-
pletion of neoadjuvant treatment and surgical resection was
6.86 weeks (range, 5–11 weeks) (Fig 1). Thirty-day mortal-
ity was 2% (1 patient), and 2 other patients died in the
hospital at 51 and 95 days postoperatively (death caused
by pneumonia and recurrent cancer, respectively). Another
7 patients died within 1 year of surgical intervention, all be-
cause of recurrent cancer. Pathologic response data are avail-
able on 43 patients and have been previously reported.12
The mean, median, minimum, and maximum FACT-E
scores for all patients who completed the treatment are listed
in Table 1 (scores are missing for some time points, and all
available data are reported). FACT-E scores decreased signif-
icantly after chemoradiation at week 7 (120 vs 127 baseline,
P¼ .04) but returned to baseline before surgical intervention
(127). Similarly, scores decreased significantly after surgical
FIGURE 1. Number of patients versus waiting time between neoadjuvant
treatment and surgical intervention.Cardiovascular Surgery c Volume 137, Number 1 37
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No. Mean Median Standard deviation Standard error* Minimum Maximum
Pre-TX 40 126.8 127.0 24.0 7.34 60.3 167.0
7 weeks postTx 38 119.9 125.0 26.1 7.36 48.0 165.0
PreSx 38 127.4 137.7 28.0 7.38 45.8 167.0
1 mo postop 33 115.3 114.0 21.0 7.41 78.0 156.0
3 mo postop 33 126.7 129.5 24.8 7.44 66.0 163.0
1 y postop 28 138.6 145.8 22.1 7.49 96.0 169.0
FACT-E, Functional Assessment of Cancer Therapy–Esophageal; PreTx, Before treatment; PostTx, after treatment; PreSx, before resection; postop, postoperatively.intervention (115 at 1 month, P ¼ .02) but returned to base-
line by 3 months postoperatively (127). Changes in FACT-E
scores are shown in Figures 2 through 4. At 1 year postoper-
atively, there was a statistically significant improvement in
scores compared with those seen at baseline (127 vs 139,
P ¼ .003). FACT-E scores continued to increase over time
for patients who were alive at least 1 year after the operation
with or without disease but were observed to significantly
decrease in those who died within 1 year after surgical inter-
vention (P ¼ .0001). An increase in QOL score was associ-
ated with a significantly lower risk of death (P ¼ .04).
In analyzing the subscales of the FACT-E, there was a sig-
nificant decrease in scores for physical and functional well-
being after neoadjuvant chemotherapy (Figures 5 and 6),
whereas emotional and social well-being scores remained
fairly stable.
The esophageal cancer–specific concerns reflected in the
esophageal cancer subscale improved with neoadjuvant che-
moradiation and then decreased after surgical intervention
but recovered by 3 months and then increased over time
(Figure 7).
Importantly, dysphagia was improved or relieved with
preoperative treatment in two thirds of patients in whom it
was a presenting complaint (data not shown). Only 6 pa-
tients required feeding tubes in this trial, 2 inserted before
the start of treatment because of poor nutritional status and
4 inserted during chemoradiation.
Similarly, eating and swallowing indices12 increased sig-
nificantly with neoadjuvant therapy. After surgical interven-
tion, there was a decrease in both scores but only minimally
FIGURE 2. Mean Functional Assessment of Cancer Therapy–Esophageal
(FACT-[E]) scores versus time: patients alive at 1 year (n¼ 33). Pretx, Be-
fore treatment; neo, 7 weeks after initiation of neoadjuvant therapy; presx,
before resection; postsx, after resection.38 The Journal of Thoracic and Cardiovascular Surgfor swallowing, whereas the eating score decreased signifi-
cantly. By 3 months postoperatively, the swallowing index
was back to preoperative levels and then continued to im-
prove. The eating index was slower to recover but steadily
increased over the ensuing 24 months that these patients
were followed.
The induction regimen was well tolerated, with low rates
of grade 3 or 4 anorexia (14 patients), fatigue (12 patients),
nausea/vomiting (10 patients), and diarrhea (10 patients).
Febrile neutropenia occurred in 8 patients, with grade 4 neu-
tropenia in 13 patients.
DISCUSSION
Although combined modality therapy (chemotherapy/
radiation therapy/surgical intervention) is arduous and pro-
longed, its effect onHRQOL in patients with operable esoph-
ageal cancer is transient as because HRQOL scores return to
baseline levels after induction and before surgical interven-
tion. Similarly, surgical intervention has a significant effect
on HRQOL because FACT-E scores decrease significantly
1 month after surgical intervention but again return to
baseline levels within 3 months of surgical intervention. Sig-
nificantly greater increases in FACT-E scores were observed
in patients who were still alive 1 year after surgical interven-
tion with or without disease but were observed to decrease in
those who died within 1 year of surgical intervention.
Our findings are in contrast to previous work by Blazeby
and colleagues using the European Organization for
FIGURE 3. Mean Functional Assessment of Cancer Therapy–Esophageal
(FACT-[E]) scores versus time: died before 1 year (n ¼ 17). Pretx, Before
treatment; neo, 7 weeks after initiation of neoadjuvant therapy; presx, before
resection; postsx, after resection.ery c January 2009
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OES 18, who reported that patients 3 to 4months after esoph-
agectomy have poorer QOL scores compared with that at
baseline.13,14 Others have reported that patients after esoph-
agectomy have a poorer QOL score compared with the nor-
mal population, which is not entirely unexpected.15 It is not
clear why the patients in our study reported QOL scores sim-
ilar to baseline values 3months after esophagectomy.Wehad
similar findings in patients after esophagectomy who had not
been treated with induction chemoradiotherapy. This does
not seem to be related to the QOL instrument used, because
Brooks and associates,16 using the FACT-E, also reported re-
duced QOL scores 3 months after esophagectomy and found
that QOL scores did not return to baseline until 9months after
esophagectomy. They also reported that the patients who re-
ceived induction chemoradiation did not regain baseline
HRQOL scores, even beyond 9 months. Although not de-
tailed, most likely 5-fluoruracil-cisplatin–based therapy
was used because that was the standard practice at the time
of their study. It was our impression that the combination
of irinotecan and cisplatin seemed to be associated with
less dysphagia and esophagitis compared with 5 fluoroura-
cil-cisplatin and that the regimen used in our study was
well tolerated, with almost no need for nutritional support
and low rates of fatigue, anorexia, diarrhea, and nausea.
FIGURE 4. Mean Functional Assessment of Cancer Therapy–Esophageal
(FACT-[E]) scores versus time (n ¼ 50). Pretx, Before treatment; neo, 7
weeks after initiation of neoadjuvant therapy; presx, before resection;
postsx, after resection.
FIGURE 5. Physical well-being scores. Pretx, Before treatment; neo, 7
weeks after initiation of neoadjuvant therapy; presx, before resection;
postsx, after resection.The Journal of Thoracic andWhether the difference in chemotherapy accounts for the dif-
ference in findings is open to question but supports the need
for assessment of QOL in future clinical trials.
In analyzing the FACT-E subscales, it is an interesting ob-
servation that the physical and functional well-being scales
decrease after neoadjuvant chemoradiation and again after
surgical intervention, whereas the emotional and social
well-being scales remain stable. This points to the resilience
of the patient’s perception of social and emotional support,
despite physical and functional debility.
The EORTC-QLQ 30 and OES 18 have been used for
much of the research in assessing HRQOL in patients with
esophageal cancer in Europe. The EORTC-QLQ 30 has
good correlation with the FACT, except in the social func-
tion role. The FACT social well- being domain focuses on
sociability and social support, whereas the QLQ 30 social
role reflects social activity limitations. The OES 18 and
Esophageal Cancer subscale also have good correlations,
especially with respect to eating and swallowing.11-16
The operative approach might influence HRQOL, at least
in the early postoperative period. de Boer and coworkers17
reported decreased QOL scores 3 months after transthoracic
esophagectomy compared with those after transhiatal esoph-
agectomy, but these differences resolved subsequently.17
In our series a variety of surgical approaches were used,
FIGURE 6. Functional well-being scores. Pretx, Before treatment; neo, 7
weeks after initiation of neoadjuvant therapy; presx, before resection;
postsx, after resection.
FIGURE 7. Esophageal subscale scores. Pretx, Before treatment; neo, 7
weeks after initiation of neoadjuvant therapy; presx, before resection;
postsx, after resection.Cardiovascular Surgery c Volume 137, Number 1 39
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complications are not provided in the reports by Blazeby
and colleagues or Brooks and associates.
Postoperative complications, including anastomotic leak,
cardiopulmonary complications, and operative technical
complications, have been reported to affect HRQOL at 6
months’ follow-up.18 We found no significant correlation
between complications and HRQOL scores at 6 months
compared with baseline scores when we examined the effect
of anastomotic leak, pneumonia, respiratory failure, and
postoperative sepsis (data not shown). However, this might
be related to the small sample size of our study.
Significant but transient adverse effects on HRQOL re-
lated to neoadjuvant chemoradiotherapy were reported by
Bottomley and associates,19 but as found in our study, scores
returned to baseline levels before surgical intervention.
However, others have reported that patients who had preop-
erative chemoradiotherapy did not achieve their baseline
QOL score, even at 9 months.16 Reynolds and colleagues20
reported overall HRQOL scores did not return to baseline
levels after either surgical intervention alone or neoadjuvant
chemoradiation followed by surgical intervention until 6
months postoperatively, and even at 12 months there were
significantly reduced scores in terms of physical and func-
tional roles, but there was no difference between the groups.
When we examined the component subscales of the FACT
in our patients, we found that the physical and functional
well-being scores were less than baseline scores at 6 months,
but the functional well-being score was back to baseline by
12 months, whereas the physical well-being score lagged
slightly. Nevertheless, combining all component subscales,
the overall QOL scores were greater than baseline values.
In a randomized study of chemoradiation versus chemora-
diation plus surgical intervention, HRQOL scores were signif-
icantly worse at the first follow-up visit (3 months) in the
surgical patients, but this difference resolved by the second
visit at 6months, and over time,HRQOLscores remained sim-
ilar in both arms.21 This supports our finding that the effect of
neoadjuvant chemoradiationonHRQOLscore is transient, and
this strategy should be pursued in an effort to improve survival.
Several groups have suggested the baseline HRQOL
scores are predictive of survival. Blazeby and colleagues14
reported that baseline HRQOL scores were not associated
with postoperative morbidity but were significantly associ-
ated with survival at 6 months postoperatively after adjust-
ing for known risk factors. A similar finding has been
reported for patients treated with primary radiotherapy,
and in particular, physical function role at baseline was pre-
dictive of survival.21,22 We did not find an association be-
tween baseline HRQOL score and early postoperative
survival (P ¼ .80); however, our sample size is small, and
there were only 3 deaths in the first 6 months. We did, how-
ever, find that increasing FACT-E scores postoperatively
over time were predictive of improved survival (P ¼ 0.04).40 The Journal of Thoracic and Cardiovascular SurgCombined modality therapies should continue to be ex-
plored in an effort to improve survival in this devastating
disease. HRQOL should be assessed in addition to patho-
logic response rates and survival. Measurement of HRQOL
provides investigators with an added dimension with which
to compare different treatment regimens in a disease in
which improvements in survival are modest and treatment
morbidity and toxicities are considerable.
We thank Pfizer for generously supported this study by provid-
ing irinotecan for the study patients.
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Discussion
Dr Kenneth A. Kesler (Indianapolis, Ind). For many years, we
have measured indicators, such as operative mortality, levels of
morbidity, and cure rates, to determine the success of treatment
for locally advanced esophageal cancer, and we have made reason-
able progress with respect to all of these particular variables over
time. The operative risks for these operations have become accept-
able. Induction therapy with cisplatin-based chemotherapy and
concurrent radiation therapy has, for the most part, become ac-
cepted as the treatment of choice for patients with adequate perfor-
mance status. As the authors of this study point out, however,
overall survival improvements with induction therapy have been
unfortunately modest, and meaningful survival benefits are proba-
bly limited to the subset of patients who demonstrate a significant or
complete pathologic response. Until we have some mechanism to
identify the subset of patients who will significantly benefit from
platin-based induction therapy or, better yet, we have more effec-
tive chemotherapy agents, many patients with locally advanced
esophageal cancer will not only not derive survival benefit from in-
duction therapy but, as this prospective study demonstrates, will ex-
perience morbidity, including a temporary loss of QOL, which is
significant in patients with limited median survival.
We therefore acknowledge the efforts of Dr Darling and her col-
leagues inToronto, who have taken the next step tomeasureHRQOL
as an important outcome variable. This study will not only serve as
a point of reference with respect to QOL outcomes for this particular
induction treatment strategy but hopefully as a starting point at which
QOL instruments are routinely included in future prospective clinical
trials for locally advanced esophageal cancer.
I have 3 questions. In this study you used the FACT-E question-
naire to quantitate HRQOL, which is an instrument you have
validated in a previous study. Do you believe, however, future re-
finements to this instrument might be helpful, such as refinements
to better capture potentially serious side effects after esophagec-
tomy, such as dumping, reflux, or delayed gastric emptying, which
might not be identified with this instrument or any other currently
used instruments for that matter?
Dr Darling. Thank you, Dr Kesler. I think that is a very good
point.
The item generation for the esophageal cancer subscale was de-
veloped from patients with recently diagnosed esophageal cancer
rather than from patients after esophagectomy. I agree that it prob-
ably does not completely address postesophagectomy problems.
We have not initiated any refinements, but I think it warrants further
study. I think that we are seeing a little bit of those problems whenThe Journal of Thoracic and Cwe look at the eating index after surgical intervention. As we who
treat these patients all know, their eating can be significantly af-
fected by dumping syndrome or other problems after esophagec-
tomy, and I think that is being reflected in the eating index.
However, it is probably worthwhile for us to take another look at
it and to address some of those postesophagectomy issues.
Dr Kesler. Although the patients in this study returned to base-
line HRQOL scores relatively quickly after both induction therapy
and esophagectomy, the baseline score was measured after disease
diagnosis. At diagnosis, most of these patients were symptomatic
with dysphagia and weight loss, not to mention having experienced
the psychologic consequences of being told they have a cancer that
is not frequently cured. Do you think it is possible to somehow
establish a baseline HRQOL score reflecting both physical and
mental status before illness that would help differentiate the effect
of the disease from the effect of the treatment and additionally pro-
vide a more accurate reference point to compare against QOL mea-
surements over time?
Dr Darling. That is a very good question also. I think it would
be difficult because most of these patients are referred already
knowing the diagnosis. The fact that the emotional well-being
score remains stable throughout the treatment protocol and there-
after speaks to the resilience of some of these patients with respect
to that component of QOL. Therefore I do not think that it would
be particularly different if we somehow picked them up before
they actually had the diagnosis. We know that if we compare
QOL with the Short Form–36 (SF-36), which is designed for
normal persons, and measure QOL in patients with cancer, more
specifically esophageal cancer, that their QOL is significantly
less than we would see in healthy subjects, but I am not sure
how to capture them before they have actually been given the
diagnosis.
Dr Kesler. Lastly, the finding that patients who died within 1
year of diagnosis, presumably of recurrent disease, demonstrated
a significant decrease in QOL compared with 1-year survivors
seems fairly intuitive and would be expected. Did the decrease in
QOL observed in these patients happen to precede any clinical or
radiographic evidence of cancer? As a corollary, do you think
this represents a potential marker that can be clinically useful to
detect recurrence?
Dr Darling. The decrease in QOL scores did precede the radio-
logic diagnosis of recurrence. These patients were all on study, and
therefore they were receiving routine computed tomographic scans
looking for recurrence. But the QOL scores decreased and were not
recovering before any imaging changes, and therefore we were al-
ready worried. I am sure we all have had those patients in our prac-
tice. They just do not get better after esophagectomy, and you are
trying to figure out why. I think the FACT-E might be clinically
useful in the future as a marker for recurrent disease. I have cer-
tainly already adopted it. When I have that patient who is just not
getting better, I start looking harder. Just to be clear, these patients
were not aware that they had recurrence, and we were not aware
that they had recurrence at the time those questionnaires were com-
pleted. I do think it will be a useful marker.
Dr Kesler. Thank you. Congratulations.
Dr Darling: Thank you very much.
DrScott J. Swanson (NewYork, NY). I would like to follow up on
that last point because it is very intriguing.Doyou think if you hadnotardiovascular Surgery c Volume 137, Number 1 41
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Soperated on those patients that theywould have had a steady decrease
in their QOL scores? Is there something about the operation or the in-
tensity of the treatment unmasking their ability to handle cancer, and
is it actually speeding up dissemination in some way? What do you
think is the actual mechanism that is going on there?
Dr Darling. We know historically that patients who were not
cured by means of esophagectomy had a median survival of 9 to
12 months. I think we are actually just seeing that same time course
in these patients for whom our treatment protocol did not improve
their survival. I do not think it is the effect of the operation or the
induction that causes that decrease in QOL score. I think we would
have seen it anyway.
Dr Douglas E. Wood (Seattle, Wash). Gail, I am interested in
whether you think that the scale that you used, a cancer-specific
QOL scale, might be indeed what we want to capture, or might
we actually be interested in a more general QOL scale, such as
SF-36, for these patients? This is very important work. There is
clearly a bias in our medical colleagues that patients have a poor
QOL relating to treatment, including esophagectomy, for esopha-
geal cancer. I do not know enough about the scale that you used
to know the differences and the nuances and whether our argument
might be stronger if we chose a generalized scale.42 The Journal of Thoracic and Cardiovascular SurgDr Darling. Well, I think they are complementary. If you want
to compare a healthy population with a disease-specific population,
a cancer population, you can use the SF-36. Therefore it depends on
your question. We are particularly interested in comparing cancer
therapies. We are trying to cure more esophageal cancer but at
a price of the toxicity. Therefore our goal in using a cancer-specific
instrument was to use it in the future for comparing different treat-
ment protocols. The SF-36would be useful in addressing a different
question, such as whether patients with esophagectomy get back to
a ‘‘normal’’ QOL score.
Dr Alec Patterson (St Louis, Mo). Gail, I enjoyed the article.
I noticed that 20% of the patients did not complete the program.
Dr Darling. Yes.
Dr Patterson. Were they all from Toronto? I mean, did you
have any handle on the quality of the induction therapy?
Dr Darling. They were essentially all from Toronto. Some of
the chemotherapy was delivered elsewhere, but in fact, all the pa-
tients who did not complete it were actually at our center. Some
were patients who were not overly enthusiastic about chemother-
apy and were not tolerant of any side effects. They did not stop
for specific toxicity reasons. It was not a case of an outside oncol-
ogist not supporting the trial.ery c January 2009
